![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/2/23/Selexipag.svg/640px-Selexipag.svg.png&w=640&q=50)
Selexipag
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Selexipag?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).[3][4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[5] It is taken by mouth or administered intravenously.[3][6]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Uptravi |
Other names | ACT-293987, NS-304 |
License data | |
Routes of administration | By mouth, intravenous |
Drug class | prostacyclin receptor agonist |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 49% |
Protein binding | 99% |
Metabolism | Activation by carboxylesterases, inactivation by CYP2C8 and others |
Metabolites | ACT-333679, the free acid (active metabolite) |
Elimination half-life | 0.8–2.5 h (selexipag) and 6.2–13.5 h (ACT-333679) |
Excretion | 93% faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.237.916 ![]() |
Chemical and physical data | |
Formula | C26H32N4O4S |
Molar mass | 496.63 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Close
The most common side effects include headache, diarrhea, nausea and vomiting, jaw pain, myalgia (muscle pain), pain in the limbs, arthralgia (joint pain) and flushing.[4]
It is available as a generic medication.[7]